Urinary urgency

Urovant Sciences® Announces Partnership with Thinx Inc. to Help Americans with Overactive Bladder This Travel Season

Retrieved on: 
Monday, November 14, 2022
Biotechnology, General Health, Pharmaceutical, Health, Puberty, Multimedia, Headache, Urinary incontinence, Overactive bladder, Incontinence, Nasal congestion, Mayo Clinic, Upper respiratory tract infection, Vitamin, Digoxin, PureWow, Lisa Filipetto, Urinary urgency, InStyle, Partnership, Liver, Family medicine, Vibegron, Good Housekeeping, THINX, Travel, Diarrhea, Publication, FDA, Sore throat, Kidney, OAB, Commercial, Orange County Business Journal, WWD, Menstruation, Urine, PLOS One, Urination, Breast milk, NYSE, Medicine, Thinx, Science, Urinary retention, BioMed Central, Nausea, The Journal of Urology, Allergy, Research, 100 Best Workplaces in Europe, Urinary tract infection, Gesellschaft mit beschränkter Haftung, Leakage, Patient, Pharmaceutical industry, Phosphorus, Management, Dietary supplement, Medical device, VideoRay UROVs, Urology

View the full release here: https://www.businesswire.com/news/home/20221114005347/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221114005347/en/
    Urovant Sciences Announces Partnership with Thinx Inc. to Help Americans with Overactive Bladder This Travel Season (Graphic: Business Wire)
    November is Bladder Health Awareness Month and its also the start of holiday and winter travel.
  • To help people learn more about OAB and ways to manage symptoms, a free travel kit is available on TimeToGo.com.
  • Overactive bladder (OAB) is a clinical condition that occurs when the bladder muscle contracts involuntarily.
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

Urovant Sciences Announces Publication of Pharmacokinetic Data on GEMTESA® (Vibegron 75mg) Administered as an Intact or Crushed Tablet

Retrieved on: 
Thursday, October 27, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Perception, Gesellschaft mit beschränkter Haftung, Medicine, Overactive bladder, Plasma, Liver, Breast milk, Instagram, Safety, 100 Best Workplaces in Europe, Vitamin, Taste, AES, Headache, AUC, Kopp, Adult, Orange County Business Journal, Drug development, I, Sex, Diarrhea, Digoxin, Neurogenic bladder dysfunction, FDA, Burden, Patient, Food additive, Urination, Food, Kidney, Urinary incontinence, Man, Science, Twitter, OAB, Urinary urgency, Vibegron, Nausea, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Sore throat, Urine, Urinary retention, Prevalence, NYSE, Upper respiratory tract infection, Nasal congestion, Urinary tract infection, Vats, Allergy, Dysphagia, Nocturia, Constipation, Public health, Pharmaceutical industry, Medical imaging, Perfume, Dietary supplement, Sexton, Cmax

In the study, which involved healthy adults, GEMTESA was administered in a single 75-mg dose as an intact tablet vs. crushed and mixed with applesauce.

Key Points: 
  • In the study, which involved healthy adults, GEMTESA was administered in a single 75-mg dose as an intact tablet vs. crushed and mixed with applesauce.
  • All patients received one treatment with intact tablet and one with crushed tablet, mixed with applesauce.
  • Additional reported TEAEs experienced by 2 participants were constipation (crushed, 13.3%; intact 6.7%) and nausea (crushed 6.7%, intact 0%) .
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

Urovant Sciences® Receives “Best in Category” Award for Abstract Highlighting Investigational Novel Gene Therapy, URO-902, Presented at 2022 International Continence Society Conference

Retrieved on: 
Thursday, September 8, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Safety, Trial of the century, Medical school, Professor, Central European Time, Injection, Anatomy, Urinary urgency, CET, American Urological Association, Overactive bladder, Gesellschaft mit beschränkter Haftung, Patient, Female, Catheter, Urinary bladder, Department, Time in Europe, FDA, Beaumont Hospital, Abstract (summary), ICS, Beaumont, Cystoscopy, International Continence Society, Micturition syncope, NYSE, Urinary tract infection, Urination, Urinary incontinence, Science, Oakland University, Nocturia, OAB, BJU International, Urine, Pharmaceutical industry, Category, Urology, VideoRay UROVs

The award-winning abstract was presented at the 2022 International Continence Society annual meeting on September 8, 2022.

Key Points: 
  • The award-winning abstract was presented at the 2022 International Continence Society annual meeting on September 8, 2022.
  • The 2022 ICS Annual meeting is being held September 7-10, 2022, in a hybrid format with both online and in person participation (Vienna, Austria).
  • The podium presentation at ICS 2022 took place on Thursday, September 8, at 10:20 Central European Time (CET).
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

Urovant Sciences® Named 17th on the List of Fortune® Best Workplaces in BioPharma™ (2022)

Retrieved on: 
Wednesday, September 7, 2022
Clinical Trials, Human Resources, Biotechnology, Seniors, Other Science, Health, Research, Professional Services, Consumer, Publishing, Science, Nursing, Communications, Medical Supplies, Other Health, FDA, Practice Management, Physical Therapy, Managed Care, Pharmaceutical, Business, Medical Devices, Infectious Diseases, Hospitals, Fitness & Nutrition, People, Work, CEO, Man, Culture, Kopp, I, Upper respiratory tract infection, Organization, Urinary retention, Urinary urgency, Medicine, Urine, Overactive bladder, Twitter, Orange County Business Journal, Adult, Gesellschaft mit beschränkter Haftung, Nausea, Patient, Health, Sex, Great Places, Kidney, The Last Best Place, Vitamin, Headache, FDA, Nasal congestion, Diarrhea, Public health, Liver, LinkedIn, Multimedia, Instagram, Breast milk, 100 Best Workplaces in Europe, Sore throat, NYSE, Urinary tract infection, Vats, Achievement, Urinary incontinence, Urination, Allergy, Digoxin, Neurogenic bladder dysfunction, Nocturia, Burden, Feedback, Place, OAB, Health insurance, Management, Pharmaceutical industry, Risk management, Dietary supplement, Biopharma LLC, Sexton, Fortune, VideoRay UROVs

Great Place to Work and Fortune magazine have named Urovant Sciences as one of the 2022 Best Workplaces in BioPharma .

Key Points: 
  • Great Place to Work and Fortune magazine have named Urovant Sciences as one of the 2022 Best Workplaces in BioPharma .
  • Its an honor to be recognized by Fortune and Great Place to Work, said James Robinson, CEO of Urovant Sciences.
  • The Fortune Best Workplaces in BioPharma list is highly competitive.
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo and Powered by People and Possibilities are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland

Retrieved on: 
Tuesday, July 5, 2022
Biotechnology, Pharmaceutical, Health, Patient, OAB, Urine, BPH, Gesellschaft mit beschränkter Haftung, Headache, Quality of life, Overactive bladder, Digoxin, Group, Urinary incontinence, Liver, FDA, Life, European Economic Area, Nasal congestion, Breast milk, NYSE, Vitamin, Sore throat, Diarrhea, Twitter, Urinary urgency, LinkedIn, Man, Urination, Partnership, Derma, Mississippi, Health, Urinary tract infection, Nausea, Pierre Fabre, USD, Adult, Allergy, BJU International, Urinary retention, Kidney, Pharmacy, Medicine, Upper respiratory tract infection, Science, Nocturia, Pharmaceutical industry, Fine chemical, Dietary supplement, Urology, VideoRay UROVs

Urovant Sciences and Pierre Fabre will share responsibility for vibegron clinical trials in the pediatric populations in Europe.

Key Points: 
  • Urovant Sciences and Pierre Fabre will share responsibility for vibegron clinical trials in the pediatric populations in Europe.
  • As part of the transaction, Urovant Sciences will also provide manufacturing services to Pierre Fabre.
  • 2011;108(7):1132-1138. doi:10.1111/j.1464-410X.2010.09993.x
    UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.
  • PIERRE FABRE, the PIERRE FABRE logo are trademarks of Pierre Fabre Medicament SAS, registered in the U.S and in other countries.

Urovant Sciences® Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association Meeting

Retrieved on: 
Friday, May 13, 2022
Health, Genetics, Clinical Trials, General Health, Pharmaceutical, Biotechnology, American Urological Association, Urination, Sex, Medicine, Urinary urgency, Urine, Sore throat, Overactive bladder, Vitamin, Neurogenic bladder dysfunction, Female, Nasal congestion, Urinary incontinence, Headache, Twitter, Science, Oakland University, Burden, Allergy, Nausea, Professor, Journal, Liver, Breast milk, Woman, Medical school, Beaumont, Vats, The Journal of Urology, Man, Urinary tract infection, Trial of the century, Diarrhea, NYSE, Department, Urinary retention, Catheter, Kopp, Digoxin, Doctor of Philosophy, I, Micturition syncope, Beaumont Hospital, Patient, OAB, Adult, FDA, Public health, LinkedIn, MD, Kidney, Upper respiratory tract infection, Population, Injection, Nocturia, Cystoscopy, Gesellschaft mit beschränkter Haftung, Safety, Pharmaceutical industry, Dietary supplement, Urology, Sexton

This was a prespecified, 12-week interim analysis of a 48-week multicenter, randomized, double-blind, placebo-controlled, dose-escalation study ( NCT04211831 ).

Key Points: 
  • This was a prespecified, 12-week interim analysis of a 48-week multicenter, randomized, double-blind, placebo-controlled, dose-escalation study ( NCT04211831 ).
  • Treatment-emergent adverse events occurred in 45.5% of patients receiving URO-902 24 mg, 46.2% receiving 48 mg, and 50.0% receiving placebo.
  • We are encouraged by these promising interim safety and efficacy findings for URO-902, said Sef Kurstjens, MD, PhD, Executive Vice President and Chief Medical Officer of Urovant Sciences.
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo, GEMTESA, and the GEMTESA logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

Urovant Sciences Announces Publication of EMPOWUR Trial Subgroup Analysis Showing Similar Efficacy for GEMTESA® in Dry and Wet Overactive Bladder Populations

Retrieved on: 
Tuesday, April 19, 2022
Health, Pharmaceutical, Overactive bladder, Urinary urgency, Urination, Woman, Population, Urinary tract infection, Drug, Patient, Sore throat, LinkedIn, Vibegron, Nocturia, Allergy, Urinary incontinence, Journal, FDA, Upper respiratory tract infection, Diarrhea, Breast milk, Adult, Paced Auditory Serial Addition Test, Hypertension, Incidence, Digoxin, The Journal of Urology, Canadian International Council, Liver, Man, Senior, Nausea, Vitamin, International Journal of Clinical Practice, Medicine, Twitter, MD, Urinary retention, Safety, OAB, Kidney, Nasal congestion, Common, Gesellschaft mit beschränkter Haftung, Urine, Headache, NYSE, Â, Science, Pharmaceutical industry, Copper, Dietary supplement, Fine chemical, Urology

The peer-reviewed paper is entitled, Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial.

Key Points: 
  • The peer-reviewed paper is entitled, Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial.
  • OAB is characterized by urgency and frequency with (OAB wet) or without (OAB dry) urge urinary incontinence (UUI).
  • The post-hoc analysis was developed to compare efficacy of vibegron vs. placebo in OAB wet and dry populations.
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo, GEMTESA, and the GEMTESA logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 2022 American Urological Association Annual Meeting

Retrieved on: 
Wednesday, April 13, 2022
Health, Genetics, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Patient, Vitamin, Breast milk, Overactive bladder, Kidney, Urinary urgency, Urination, Medicine, Public health, Woman, Cystoscopy, I, Urinary tract infection, Twitter, Adult, Nasal congestion, Incidence, Neurogenic bladder dysfunction, Urinary retention, Sore throat, Burden, Digoxin, Kopp, LinkedIn, Injection, Vats, Urine, Nocturia, Allergy, Sex, Female, Liver, Urinary incontinence, Man, Headache, NYSE, Safety, FDA, OAB, Diarrhea, Nausea, Upper respiratory tract infection, Pharmaceutical industry, Medical imaging, Dietary supplement, Urology, Sexton

URO-902 has the potential to be the first gene therapy for patients with OAB.

Key Points: 
  • URO-902 has the potential to be the first gene therapy for patients with OAB.
  • If approved, this innovative treatment has the potential to address an unmet need for patients who have failed oral pharmacologic therapies.
  • Secondary endpoints were changes from EMPOWUR baseline at week 52 in average daily micturitions, UUI, urgency, and total urinary incontinence.
  • Sumitovant is a global biopharmaceutical company leveraging data-driven insights to rapidly accelerate development of new potential therapies for unmet patient conditions.

Urovant Sciences Announces Publication of New Review of Efficacy and Safety Data for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients in the Journal Therapeutics and Clinical Risk Management

Retrieved on: 
Tuesday, March 22, 2022
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Urine, List of Dove Medical Press academic journals, Therapy, LinkedIn, Headache, Blood pressure, Upper respiratory tract infection, Hypertension, Nasal congestion, Vibegron, Diarrhea, NYSE, Overactive bladder, Digoxin, Adult, Urinary tract infection, Allergy, Urinary incontinence, Doctor of Philosophy, Kidney, Urination, Urinary retention, Woman, Incidence, Urinary urgency, Man, Medicine, Nausea, Nocturia, Breast milk, Science, MD, Safety, Review, Vitamin, Sore throat, Twitter, OAB, Sumitomo Dainippon Pharma, Heart rate, Common, Liver, AES, FDA, Patient, Dietary supplement, Pharmaceutical industry, Copper, Fine chemical, Urology, THE EMPOWUR TRIAL, THE 40-WEEK EMPOWUR EXTENSION

Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced the publication of a new review of data on GEMTESA (vibegron) 75 mg in the peer-reviewed journal, Therapeutics and Clinical Risk Management ( https://bit.ly/Vibegron ).

Key Points: 
  • Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced the publication of a new review of data on GEMTESA (vibegron) 75 mg in the peer-reviewed journal, Therapeutics and Clinical Risk Management ( https://bit.ly/Vibegron ).
  • Titled, An evaluation of the efficacy and safety of vibegron in the treatment of overactive bladder, the paper reviews published data from studies conducted over the past three years.
  • The 40-week EMPOWUR extension study evaluated safety in patients receiving GEMTESA for 52 weeks.
  • In EMPOWUR, the most frequently occurring treatment-emergent AEs (TEAEs) with incidence greater for vibegron than placebo were headache and nasopharyngitis.

Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients

Retrieved on: 
Monday, November 8, 2021
Health, Clinical Trials, General Health, Pharmaceutical, Cardiology, Biotechnology, Urine, Nocturia, Female, Kidney, Sumitomo Dainippon Pharma, Safety, Urinary tract infection, Vitamin, Upper respiratory tract infection, State university system, Pain, OAB, Hypertension, Blood pressure, Burden, Overactive bladder, Urinary incontinence, Urinary urgency, Headache, Vats, Heart rate, Sore throat, FDA, Adult, Liver, Neurogenic bladder dysfunction, Hypoglycemia, Doctor of Philosophy, Breast milk, Twitter, I, Urination, Nasal congestion, Kopp, Man, Urologic disease, Nausea, News, MD, Digoxin, Sex, Ageing, Urinary retention, Diarrhea, Phentermine, Cornelia, LinkedIn, NYSE, Public health, Allergy, Pharmaceutical industry, Medical imaging, Dietary supplement, Fine chemical, Overactive Bladder, GEMTESA®, Urovant Sciences, Sumitovant Biopharma Ltd., OVERACTIVE BLADDER, GEMTESA®, UROVANT SCIENCES, SUMITOVANT BIOPHARMA LTD.

In a dedicated, double-blind, placebo-controlled ambulatory blood pressure study of patients with OAB, once-daily treatment with GEMTESA 75 mg was not associated with statistically significant or clinically meaningful effects on blood pressure or heart rate.

Key Points: 
  • In a dedicated, double-blind, placebo-controlled ambulatory blood pressure study of patients with OAB, once-daily treatment with GEMTESA 75 mg was not associated with statistically significant or clinically meaningful effects on blood pressure or heart rate.
  • The article is entitled, Effects of Vibegron on Ambulatory Blood Pressure in Patients with Overactive Bladder: Results from a Double-Blind, Placebo-Controlled Trial.
  • The published data substantiate that compared with placebo, GEMTESA has no statistically significant or clinically meaningful impact on blood pressure."
  • The ambulatory blood pressure study enrolled 214 patients with OAB, aged between 40-75 years.